NVID Receives U.S. Letters Patent

ARCHIVED 2002–2016: Originally distributed via the eWire press wire service. Preserved as historical record.

SUBSCRIBE/UNSUBSCRIBE |

Conservation & Wildlife

Corporate Responsibility

Science & Technology

Syndication Partners

**************************************************************************

E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE E-WIRE PRESS RELEASE

**************************************************************************

TO BUSINESS AND ENVIRONMENTAL EDITORS:

NVID Receives U.S. Letters Patent

Revolutionary Ionic Silver Antimicrobial Technology

FLORIDA, CLEARWATER, Mar. 8 -/E-Wire/-- NVID International, Inc. (Pink Sheets:NVID) today announced the U.S. Patent and Trademark Office has issued a U.S. Letters Patent on NVID's ionic silver antimicrobial technology Axenohl. The U.S. Letters Patent No. 6,197,814 covers one of multiple inventive aspects of NVID's Axenohl antimicrobial technology.

NVID has also recently filed a U.S. Divisional Patent Application, and intends to file multiple Divisional Applications for additional patent coverage on other inventive aspects of the Axenohl antimicrobial technology.

Patent applications outside the United States have been filed to date in the following countries and regions based upon NVID's Patent Cooperation Treaty (PCT) patent application. The World Intellectual Property Organization published the application on April 22, 1999 under publication Number WO 99/18790.

Nations: Australia, Brazil, Canada, China, Japan, Mexico and New Zealand.

Regions: ARIPO Patent: Ghana, Gambia, Kenya, Lesotho, Malawi, Sudan, Swaziland, Uganda and Zimbabwe.

Eurasian Patent: Armenia, Azerbaijan, Belarus, Kyrgystan, Republic of Moldova, Russian Federation, Tajikistan, and Turkmenistan.

European Patent: Austria, Belgium, Switzerland, Liechtenstein, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Ireland, Italy, Luxembourg, Monaco, Netherlands, Portugal, and Sweden.

OAPI Patent: Burkina, Faso, Benin, Central African Republic, Congo, Guinea, Bissau, Coted'Ivoire, Cameroon, Gabon, Guinea, Mauritania, Niger, Senegal, Chad and Togo.

"The U.S. Letters Patent No. 6,197,814 from the U.S. Patent and Trademark Office now gives NVID patent protection on Axenohl in the U.S. to 2018. NVID is also optimistic for patenting Axenohl in foreign countries,' commented David J. Larson President of NVID. "This validates and strengthens the overall Axenohl market position in regards to the inventiveness and potential marketability of the Axenohl antimicrobial technology. In addition, I would especially like to thank Mr. Andrew B. Arata the Inventor of Axenohl, on behalf of all the NVID shareholders for his commitment to this project over the years.'

Axenohl is a non-toxic antimicrobial technology that incorporates the biocidal properties of stabilized ionic silver to kill bacteria, viruses and fungi. Axenohl does not include the use of traditional disinfectants such as quaternary ammonium salts, phenols, glutaraldehyde, chlorine or bromine compounds. The Axenohl formulations have been designed to compete and / or replace these products while eliminating the associated environmental hazards. Axenohl technology exhibits strong biocidal activity, a broad spectrum of kill and sustained activity against a wide range of disease causing microorganisms. The disinfection efficacy of Axenohl has been well documented by independent testing laboratories. Axenohl eliminates the following test organism strains all within one minute and 99.9999% efficacy.

Pseudomonas aeruginosa ATCC 15442 Staphylococcus aureus ATCC 6538 Salmonella cholerasuis ATCC 10708 E. Coli ATCC 0157:H7 Listeria monocytogenes ATCC 11543 Enterococcus faecium ATCC 11543 Rhinovirus (common colds) Rotavirus (infectious diarrhea) Vancomycin-resistant-enterococci (VRE)

Target markets for NVID's patented ionization disinfection technologies include; hospital and nursing home water systems, point-of-use / point-of-entry; municipal, commercial and residentialdrinking water systems, FDA compliant consumer products, pools / spas, cisterns / wells, veterinary, horticulture, agriculture and food processing applications.

About NVID International, Inc.

NVID International, Inc. based in Clearwater, Florida manufactures and markets patented ionization disinfection technologies that substantially reduce or replace traditional disinfectants such as quaternary ammonium salts, phenols, and chlorine or bromine based halogens.

The matters discussed in this news release are forward-looking statements with respect to the future activities of the Company. These forward-looking statements by their vary nature involve risks and uncertainties and represent the Company's judgement as of the date of this release.

NVID International, Inc.

NVID International, Inc. and Aqua Bio Technologies, Inc. can be reached

at: Corporate Office: 28163 U.S. 19 N. Suite 302 Clearwater, Florida

33761 Contact: David Larson Phone (727) 669-5005 x1, Fax (727) 669-4701

e-mail [REDACTED-EMAIL] Sales Office: 5153 Sandy Cove Avenue

Sarasota, Florida 34242 Contact: Michael Redden Phone (941) 312-9100 Fax

(941) 312-9300 e-mail [REDACTED-EMAIL]

http://aquabiotech.net

**************************************************************************

To Transmit Your News Over E-Wire, visit http://www.ewire.com or

call 1-[REDACTED-PHONE]. E-Wire Is Broadcast To Millions Of Readers Worldwide

**************************************************************************